Extranodal Nasal-Type NK/T-Cell Lymphoma Treatment: Analysis from a Multicenter Study

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Extranodal natural killer/T-cell lymphoma, nasal type (ENKL) is a rare and aggressive non-Hodgkin lymphoma.
• ENKL is the primary cause of the clinical syndrome known as fatal midline granuloma.
• Understanding ENKL treatment outcomes is crucial for improving patient survival and quality of life.

Purpose of the Study:

• To evaluate the treatment outcomes of extranodal natural killer (NK)/T-cell lymphomas.
• To identify prognostic factors and treatment responses in ENKL patients.
• To assess the impact of anthracycline-free regimens on ENKL survival.

Main Methods:

• Retrospective analysis of data from 39 patients across 15 centers.
• Evaluation of patient characteristics, risk status, and treatment regimens.
• Observation of treatment responses and survival outcomes.

Main Results:

• A 53.8% complete response rate was observed with first-line therapy.
• Median overall survival was 16 months.
• Mortality reached 56.4% in patients with advanced disease.

Conclusions:

• Anthracycline-free treatments have improved the prognosis for ENKL patients.
• Despite treatment advancements, high mortality persists in advanced ENKL.
• Further research is needed to optimize ENKL treatment strategies, particularly for advanced stages.